Stoke Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell STOK and other ETFs, options, and stocks.

About STOK

Stoke Therapeutics, Inc. is a biotechnology company, which engages in the research and development of treatments for genetic diseases. It offers a wide range of relevant tissues including the central nervous system, eye, kidney, and liver. 

CEO
Ian Frederick Smith
CEOIan Frederick Smith
Employees
170
Employees170
Headquarters
Bedford, Massachusetts
HeadquartersBedford, Massachusetts
Founded
2014
Founded2014
Employees
170
Employees170

STOK Key Statistics

Market cap
1.85B
Market cap1.85B
Price-Earnings ratio
-10.66
Price-Earnings ratio-10.66
Dividend yield
Dividend yield
Average volume
630.59K
Average volume630.59K
High today
$30.27
High today$30.27
Low today
$29.58
Low today$29.58
Open price
$30.01
Open price$30.01
Volume
160.54K
Volume160.54K
52 Week high
$40.22
52 Week high$40.22
52 Week low
$9.09
52 Week low$9.09

Stock Snapshot

As of today, Stoke Therapeutics(STOK) shares are valued at $29.74. The company's market cap stands at 1.85B, with a P/E ratio of -10.66.

During the trading session on 2026-05-21, Stoke Therapeutics(STOK) shares reached a daily high of $30.27 and a low of $29.58. At a current price of $29.74, the stock is +0.5% higher than the low and still -1.8% under the high.

Trading volume for Stoke Therapeutics(STOK) stock has reached 160.54K, versus its average volume of 630.59K.

The stock's 52-week range extends from a low of $9.09 to a high of $40.22.

The stock's 52-week range extends from a low of $9.09 to a high of $40.22.

STOK News

Zacks 3h
Is it a Good Idea to Invest in Stoke Therapeutics Stock Now? - Zacks Investment Research

...

Is it a Good Idea to Invest in Stoke Therapeutics Stock Now? - Zacks Investment Research
Simply Wall St 1d
Stoke Therapeutics Is Down 7.8% After Sharp Q1 Swing From Profit To Loss – What's Changed

In the first quarter of 2026, Stoke Therapeutics, Inc. reported sales of US$6.23 million and a net loss of US$50 million, reversing from much higher revenue and...

Stoke Therapeutics Is Down 7.8% After Sharp Q1 Swing From Profit To Loss – What's Changed

Analyst ratings

100%

of 12 ratings
Buy
100%
Hold
0%
Sell
0%

People also own

Based on the portfolios of people who own STOK. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.